Curewize Health

Company Overview

Snapshot

Founded in February 2013 by Jennifer Yarden, Curewize Health operates with 1-10 employees. The company has raised $1,000,000 across two funding rounds, with Youdim Pharmaceuticals and Office of the Chief Scientist among its investors. In October 2022, Curewize Health ceased to operate.

Business overview

Curewize Health is a clinical research and commercialization company focused on advancing personalized cancer treatments, particularly for children, adolescents, and young adults. Its core product family, ProALL, consists of microRNA-based predictive tests for the early diagnosis and monitoring of acute lymphoblastic leukemia patients. The company also conducts R&D for precision lab tests to guide treatment decisions based on altered miRNA patterns and is developing ProState blood tests for prostate cancer detection to prevent overtreatment. Curewize Health operates within the Health Tech & Life Sciences sector, specifically in Medical Treatment & Therapeutics and Diagnostics Devices.

Company Intelligence Q&A

What is Curewize Health's primary focus?

Curewize Health focuses on advancing personalized cancer treatments, particularly for cancers common in children, adolescents, and young adults, through clinical research and commercialization.

What is the company's lead product?

The company's lead product family is ProALL, which consists of microRNA-based predictive tests designed for the early diagnosis and monitoring of acute lymphoblastic leukemia patients.

When did Curewize Health cease operations?

Curewize Health ceased to operate in October 2022.

What is the purpose of the ProState blood tests being developed by Curewize Health?

Curewize Health is developing ProState blood tests for the detection of high-accuracy prostate cancer patients, aiming to help prevent the overtreatment of prostate cancer with radical prostatectomy surgery or radiotherapy.

What type of technology does Curewize Health utilize?

Curewize Health's platform technology is based on quantifying microRNA, which are master regulators of gene activity, for the development of diverse lab tests for personalized medicine, diagnosis, and prognosis of various diseases.